Sirt1 protects against high-fat diet-induced metabolic damage

The identification of new pharmacological approaches to effectively prevent, treat, and cure the metabolic syndrome is of crucial importance. Excessive exposure to dietary lipids causes inflammatory responses, deranges the homeostasis of cellular metabolism, and is believed to constitute a key initiator of the metabolic syndrome. Mammalian Sirt1 is a protein deacetylase that has been involved in resveratrol-mediated protection from high-fat diet-induced metabolic damage, but direct proof for the implication of Sirt1 has remained elusive. Here, we report that mice with moderate overexpression of Sirt1 under the control of its natural promoter exhibit fat mass gain similar to wild-type controls when exposed to a high-fat diet. Higher energy expenditure appears to be compensated by a parallel increase in food intake. Interestingly, transgenic Sirt1 mice under a high-fat diet show lower lipid-induced inflammation along with better glucose tolerance, and are almost entirely protected from hepatic steatosis. We present data indicating that such beneficial effects of Sirt1 are due to at least two mechanisms: induction of antioxidant proteins MnSOD and Nrf1, possibly via stimulation of PGC1α, and lower activation of proinflammatory cytokines, such as TNFα and IL-6, via down-modulation of NFκB activity. Together, these results provide direct proof of the protective potential of Sirt1 against the metabolic consequences of chronic exposure to a high-fat diet.

[1]  F. Alt,et al.  Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Gadjeva,et al.  A role for NF-kappa B subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. , 2004, Journal of immunology.

[3]  L. Montoliu,et al.  Size Matters: Use of YACs, BACs and PACs in Transgenic Animals , 2001, Transgenic Research.

[4]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[5]  L. Fernández-Salazar,et al.  Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. , 2004, Diabetes care.

[6]  Namjin Chung,et al.  Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ , 2004, Nature.

[7]  M. Gadjeva,et al.  A Role for NF-κB Subunits p50 and p65 in the Inhibition of Lipopolysaccharide-Induced Shock1 , 2004, The Journal of Immunology.

[8]  Steven P Gygi,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.

[9]  M. Permutt,et al.  Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. , 2005, Cell metabolism.

[10]  Candy S. Lee,et al.  Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Hevener,et al.  IKK-beta links inflammation to obesity-induced insulin resistance. , 2005, Nature medicine.

[12]  J. Seidell,et al.  Epidemiology of obesity. , 2002, Seminars in vascular medicine.

[13]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[14]  E. Yeh,et al.  Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NFκB-dependent transcription , 2006, Nature Cell Biology.

[15]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[16]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[17]  C. Schindler,et al.  NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. , 2006, The Journal of clinical investigation.

[18]  D. Cummings,et al.  Emerging therapeutic strategies for obesity. , 2006, Endocrine reviews.

[19]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[20]  P. Puigserver,et al.  Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.

[21]  Dunstan Cooke,et al.  The obesity pipeline: current strategies in the development of anti-obesity drugs , 2006, Nature Reviews Drug Discovery.

[22]  L. Guarente.  Sirtuins as potential targets for metabolic syndrome , 2006, Nature.

[23]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[24]  M. Tschöp,et al.  Fat fuels insulin resistance through Toll-like receptors , 2006, Nature Medicine.

[25]  Jun Wang,et al.  Neuronal SIRT1 Activation as a Novel Mechanism Underlying the Prevention of Alzheimer Disease Amyloid Neuropathology by Calorie Restriction* , 2006, Journal of Biological Chemistry.

[26]  S. Miao,et al.  The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones , 2006, Cellular and Molecular Life Sciences CMLS.

[27]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[28]  S. Yamaoka,et al.  Role of the Toll-like Receptor 4/NF-&kgr;B Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[29]  Q. Zhai,et al.  SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. , 2007, Cell metabolism.

[30]  J. Carvalheira,et al.  Loss-of-Function Mutation in Toll-Like Receptor 4 Prevents Diet-Induced Obesity and Insulin Resistance , 2007, Diabetes.

[31]  I. Rahman,et al.  Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[32]  M. Honda,et al.  Lipid‐induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet , 2007, Hepatology.

[33]  S. O’Rahilly,et al.  The Hormonal Control of Food Intake , 2007, Cell.

[34]  J. Auwerx,et al.  Sirtuin functions in health and disease. , 2007, Molecular endocrinology.

[35]  Andrew D. Steele,et al.  SIRT1 transgenic mice show phenotypes resembling calorie restriction , 2007, Aging cell.

[36]  C. Byrne,et al.  Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). , 2007, Drug discovery today.

[37]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[38]  S. Vatner,et al.  Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart , 2007, Circulation research.

[39]  S. Kaneko,et al.  Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. , 2007, Gastroenterology.

[40]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[41]  G. Perlemuter,et al.  Nonalcoholic fatty liver disease: from pathogenesis to patient care , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[42]  P. Puigserver,et al.  Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1 , 2007, Proceedings of the National Academy of Sciences.

[43]  P. Puigserver,et al.  Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. , 2008, FEBS letters.

[44]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[45]  P. Puigserver,et al.  Metabolic adaptations through the PGC‐1α and SIRT1 pathways , 2008 .

[46]  S. Imai,et al.  Age‐associated loss of Sirt1‐mediated enhancement of glucose‐stimulated insulin secretion in beta cell‐specific Sirt1‐overexpressing (BESTO) mice , 2008, Aging cell.